Versacloz (Clozapine) Patent Expiration, LOE Window & CMS Spending

Versacloz (Clozapine) by Douglas America: FDA Orange Book LOE 2028-05-01, 8 AB generics, $2.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDouglas America
FDA Application & PathwayN203479 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-05-01
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$2.1M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$705K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel